Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a $142 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech Outlines 2026 Strategy and Milestones at J.P. Morgan Healthcare Conference
- BioNTech: Stable COVID-19 Vaccine Base and Catalyst-Rich Oncology Pipeline Support Buy Rating
- BioNTech outlines 2026 areas of focus
- BioNTech Maps Out Catalyst-Rich 2026 Oncology Agenda at J.P. Morgan Healthcare Conference
- BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial